A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3002815 in Healthy Subjects

Trial Profile

A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3002815 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs LY 3002815 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 18 May 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
    • 18 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top